Last reviewed · How we verify
Sandimmun Neoral®, CellCept® and prednisolone
Sandimmun Neoral®, CellCept® and prednisolone is a Small molecule drug developed by University of Oslo School of Pharmacy. It is currently FDA-approved.
Sandimmun Neoral®, CellCept®, and prednisolone are marketed immunosuppressive drugs developed by the University of Oslo School of Pharmacy, with a key composition patent expiring in 2028. The combination of these drugs offers a robust immunosuppressive effect, which is a significant competitive advantage in preventing organ rejection post-transplant. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Sandimmun Neoral®, CellCept® and prednisolone |
|---|---|
| Sponsor | University of Oslo School of Pharmacy |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD. (NA)
- Kidney Graft Function Under the Immunosuppression Strategies (PHASE4)
- Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients (PHASE4)
- Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies (PHASE2)
- Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects (PHASE2, PHASE3)
- Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sandimmun Neoral®, CellCept® and prednisolone CI brief — competitive landscape report
- Sandimmun Neoral®, CellCept® and prednisolone updates RSS · CI watch RSS
- University of Oslo School of Pharmacy portfolio CI